Statera Biopharma Statistics
Total Valuation
Statera Biopharma has a market cap or net worth of 7,258.
| Market Cap | 7,258 |
| Enterprise Value | n/a |
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Statera Biopharma has 72.58 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 72.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.61 |
| Interest Coverage | -12.53 |
Financial Efficiency
Return on equity (ROE) is -286.94% and return on invested capital (ROIC) is -29.90%.
| Return on Equity (ROE) | -286.94% |
| Return on Assets (ROA) | -23.85% |
| Return on Capital (ROIC) | -29.90% |
| Revenue Per Employee | 80,166 |
| Profits Per Employee | -2.00M |
| Employee Count | 46 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.33% in the last 52 weeks. The beta is 250.27, so Statera Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 250.27 |
| 52-Week Price Change | -83.33% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 44.20 |
| Average Volume (20 Days) | 37,396 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.76 |
Income Statement
In the last 12 months, Statera Biopharma had revenue of 3.69 million and -91.83 million in losses. Loss per share was -1.91.
| Revenue | 3.69M |
| Gross Profit | 2.59M |
| Operating Income | -21.14M |
| Pretax Income | -91.86M |
| Net Income | -91.83M |
| EBITDA | -20.58M |
| EBIT | -21.14M |
| Loss Per Share | -1.91 |
Balance Sheet
The company has 506,098 in cash and 7.41 million in debt, giving a net cash position of -6.90 million or -0.10 per share.
| Cash & Cash Equivalents | 506,098 |
| Total Debt | 7.41M |
| Net Cash | -6.90M |
| Net Cash Per Share | -0.10 |
| Equity (Book Value) | -10.17M |
| Book Value Per Share | -0.20 |
| Working Capital | -21.01M |
Cash Flow
In the last 12 months, operating cash flow was -12.09 million and capital expenditures -103,367, giving a free cash flow of -12.19 million.
| Operating Cash Flow | -12.09M |
| Capital Expenditures | -103,367 |
| Free Cash Flow | -12.19M |
| FCF Per Share | -0.17 |
Margins
| Gross Margin | 70.27% |
| Operating Margin | -573.26% |
| Pretax Margin | -2,490.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Statera Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -103.71% |
| Shareholder Yield | -103.71% |
| Earnings Yield | -1,911,715.00% |
| FCF Yield | -168,004.05% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Statera Biopharma has an Altman Z-Score of -21.97. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.97 |
| Piotroski F-Score | n/a |